<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075112</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00065591</org_study_id>
    <nct_id>NCT02075112</nct_id>
  </id_info>
  <brief_title>Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck</brief_title>
  <acronym>RAD2412-13</acronym>
  <official_title>A Pilot Study of Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if soy supplementation during chemotherapy and
      radiation therapy will decrease side effects caused by treatment. Long-lasting dry mouth is
      a side effect of the standard treatment, and we are testing whether soy supplementation
      during treatment may reduce this symptom and other side effects of chemoradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concurrent chemoradiation is the standard of care for locally advanced squamous cell
      carcinoma of the head and neck (SCCHN). Improving the outcome for patients with this disease
      remains a major challenge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients with grade  2 or higher xerostomia at 1 year post-treatment.</measure>
    <time_frame>1 year after treatment completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome of this study is the percentage of patients with symptomatic (grade 2 or higher) xerostomia at 1 year post-treatment, assessed by the LENT/SOMA method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory biomarker studies</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline tissue levels of p16, COX-2, EGFR, and NF-kB and look for any correlations of these proteins with clinical parameters of outcome and toxicity
Baseline urinary levels of isoprostanes before treatment, and 3 and 6 months post- treatment, as a potential marker of oxidative stress associated with chemoradiation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Soy isoflavone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Treatment:Soy Isoflavone in combo w/ Radiation Therapy &amp; Cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>soy isoflavone</intervention_name>
    <description>Study Treatment:Soy Isoflavone in combo w/Radiation Therapy &amp; Cisplatin</description>
    <arm_group_label>Soy isoflavone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven SCCHN

          -  Primary disease site involving the  oropharynx

          -  Clinical stage III or IV

          -  Age ≥ 18

          -  Karnofsky Performance Status (KPS) ≥ 70

          -  Electrolytes, hepatic, renal, and hematologic functions within normal limits

          -  Amylase  and lipase levels within normal limits

        Exclusion Criteria:

          -  Prior history of SCCHN

          -  Prior history of radiation to the head and neck region

          -  KPS&lt; 70

          -  Soy allergy

          -  Contraindication to Cisplatin chemotherapy or plans to alter or reduce Cisplatin
             therapy

          -  Any head and neck cancer of non-squamous histology

          -  Any head and neck subsite other than oropharynx (including unknown primary site)

          -  Patients who are pregnant or lactating

          -  Patients who may benefit from surgical resection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kritin Higgins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristin Higgins, MD</last_name>
    <phone>404-778-1900</phone>
    <email>kristin.higgins@emory.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica M Huamani-Bundy, MS</last_name>
    <phone>404-778-5720</phone>
    <email>jhuaman@emory.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica M Huamani- Bundy, MS</last_name>
      <phone>404-778-5720</phone>
      <email>jhuaman@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chade Granderson, BS</last_name>
      <phone>404-778-3609</phone>
    </contact_backup>
    <investigator>
      <last_name>Kristin Higgins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Kristin Higgins, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Soy</keyword>
  <keyword>Isoflavone</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Cisplatin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
